Roelof Adriaan Johan Smit

Roelof Adriaan Johan Smit

Auto-generated profile, based on publicly available information

Roelof Adriaan Johan Smit

The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2016 in Circulation
Verified
Journal Article
Closed access
RSRoelof A.J. Smit
Roelof A.J. Smit
STStella Trompet
Stella Trompet
BSBehnam Sabayan
Behnam Sabayan
SCSaskia le Cessie
Saskia le Cessie
JGJeroen van der Grond
Jeroen van der Grond
JJJ. Wouter Jukema
J. Wouter Jukema
Background: Recently, it was shown that intraindividual variation in low-density lipoprotein cholesterol (LDL-C) predicts both cerebrovascular and cardiovascular events. We aimed to examine whether this extends to cognitive function and examined possible pathways using a magnetic resonance imaging substudy. Methods: We investigated the association between LDL-C variability and 4 cognitive domains at month 30 in 4428 participants of PROSPER (PROspective Study of Pravastatin in the Elderly at Risk). Additionally, we assessed the association of LDL-C variability with neuroimaging outcomes in a subset of 535 participants. LDL-C variability was defined as the intraindividual standard deviation over 4 postbaseline LDL-C measurements, and all analyses were adjusted for mean LDL-C levels and cardiovascular risk factors. Results: Higher LDL-C variability was associated with lower cognitive function in both the placebo and pravastatin treatment arms. Associations were present for selective attention ( P =0.017 and P =0.11, respectively), processing speed ( P =0.20 and P =0.029), and memory (immediate recall, P =0.002 and P =0.006; delayed recall, P =0.001 and P ≤0.001). Furthermore, higher LDL-C variability was associated with lower cerebral blood flow in both trial arms ( P =0.031 and P =0.050) and with greater white matter hyperintensity load in the pravastatin arm ( P =0.046). No evidence was found for interaction between LDL-C variability and pravastatin treatment for both cognitive and magnetic resonance imaging outcomes. Conclusions: We found that higher visit-to-visit variability in LDL-C, independently of mean LDL-C levels and statin treatment, is associated with lower cognitive performance, lower cerebral blood flow, and greater white matter hyperintensity load.

6 March 2025 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CRCarolina Roselli
Carolina Roselli
ISIda Surakka
Ida Surakka
MOMorten Olesen
Morten Olesen
GSGardar Sveinbjornsson
Gardar Sveinbjornsson
NMNicholas A Marston
Nicholas A Marston
PEPatrick T Ellinor
Patrick T Ellinor

6 March 2025 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SCSeung Hoan Choi
Seung Hoan Choi
SJSean Jurgens
Sean Jurgens
LXLing Xiao
Ling Xiao
MHMatthew C Hill
Matthew C Hill
CHChristopher M Haggerty
Christopher M Haggerty
PEPatrick T Ellinor
Patrick T Ellinor

5 December 2019 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
OCon behalf of the GIST consortium
on behalf of the GIST consortium
RSRoelof A. J. Smit
Roelof A. J. Smit
STStella Trompet
Stella Trompet
ALAaron Leong
Aaron Leong
MGMark O. Goodarzi
Mark O. Goodarzi
JJJ. Wouter Jukema
J. Wouter Jukema

4 March 2014 in Netherlands Heart Journal
Verified
Journal Article
Open access
PDF file
RSR. A. J. Smit
R. A. J. Smit
STS. Trompet
S. Trompet
ACA. J. M. de Craen
A. J. M. de Craen
JJJ. W. Jukema
J. W. Jukema
Cardiovascular disease (CVD) remains the leading cause of death in developed countries, despite the decline of CVD mortality over the last two decades. From observational, predictive research, efforts have been made to find causal risk factors for CVD. However, in recent years, some of these findings have been shown to be mistaken. Possible explanations for the discrepant findings are confounding and reverse causation. Genetic epidemiology has tried to address these problems through the use of Mendelian randomisation. In this paper, we discuss the promise and limitations of using genetic variation for establishing causality of cardiovascular risk factors.

1 March 2018 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
RSRoelof A.J. Smit
Roelof A.J. Smit
JJJohan Wouter Jukema
Johan Wouter Jukema
IPIris Postmus
Iris Postmus
IFIan Ford
Ian Ford
PSPieternella Eline Slagboom
Pieternella Eline Slagboom
STStella Trompet
Stella Trompet